Esperion Therapeutics (ESPR) has rallied over the last month. Analysts expect that President Trump is going to enact changes at the Food and Drug Administration that will allow for quicker approval of drugs, such as Esperion’s cholesterol fighting drug bempedoic acid. Should the FDA give the drug early approval, it would become the first available oral drug of its type. The drug sector can be very volatile, and ESPR shares could easily give back the recent gains on any hints that its drug will not get the FDA’s approval. The company is not operating in the profit, and last quarter it reported a loss of 77 cents per share, which was better than expected, but until the company is able to show a profit there is little reason to hold the stock at its current level. Long term shareholders are likely to show a big gain on their position, and ought to consider locking in some of those profits before any bad news drives shares lower.
Chart courtesy of www.stockcharts.com